Physiological levels of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity.
Rocca C, Scavello F, Colombo B, Gasparri AM, Dallatomasina A, Granieri MC, Amelio D, Pasqua T, Cerra MC, Tota B, Corti A, Angelone T.
Rocca C, et al. Among authors: scavello f.
FASEB J. 2019 Jun;33(6):7734-7747. doi: 10.1096/fj.201802707R. Epub 2019 Apr 11.
FASEB J. 2019.
PMID: 30973759
These findings suggest that administration of low-dose CgA to patients with low levels of endogenous CgA might represent a novel approach to prevent Doxo-induced adverse events without impairing antitumor effects.-Rocca, C., Scavello, F., Colombo, B., Gasparri, A. M …
These findings suggest that administration of low-dose CgA to patients with low levels of endogenous CgA might represent a novel approach to …